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Abstract
Background: Prostate stem cell antigen (PSCA) is a recently defined homologue of the Thy-1/Ly-6 family of
glycosylphosphatidylinositol (GPI)-anchored cell surface antigens. The purpose of the present study was to
examine the expression status of PSCA protein and mRNA in clinical specimens of human prostate cancer (Pca)
and to validate it as a potential molecular target for diagnosis and treatment of Pca.
Materials and Methods: Immunohistochemical (IHC) and in situ hybridization (ISH) analyses of PSCA
expression were simultaneously performed on paraffin-embedded sections from 20 benign prostatic hyperplasia
(BPH), 20 prostatic intraepithelial neoplasm (PIN) and 48 prostate cancer (Pca) tissues, including 9 androgen-
independent prostate cancers. The level of PSCA expression was semiquantitatively scored by assessing both the
percentage and intensity of PSCA-positive staining cells in the specimens. Then compared PSCA expression
between BPH, PIN and Pca tissues and analysed the correlations of PSCA expression level with pathological grade,
clinical stage and progression to androgen-independence in Pca.
Results: In BPH and low grade PIN, PSCA protein and mRNA staining were weak or negative and less intense
and uniform than that seen in HGPIN and Pca. There were moderate to strong PSCA protein and mRNA
expression in 8 of 11 (72.7%) HGPIN and in 40 of 48 (83.4%) Pca specimens examined by IHC and ISH analyses,
with statistical significance compared with BPH (20%) and low grade PIN (22.2%) samples (p < 0.05, respectively).
The expression level of PSCA increased with high Gleason grade, advanced stage and progression to androgen-
independence (p < 0.05, respectively). In addition, IHC and ISH staining showed a high degree of correlation
between PSCA protein and mRNA overexpression.
Conclusions: Our data demonstrate that PSCA as a new cell surface marker is overexpressed by a majority of
human Pca. PSCA expression correlates positively with adverse tumor characteristics, such as increasing
pathological grade (poor cell differentiation), worsening clinical stage and androgen-independence, and
speculatively with prostate carcinogenesis. PSCA protein overexpression results from upregulated transcription
of PSCA mRNA. PSCA may have prognostic utility and may be a promising molecular target for diagnosis and
treatment of Pca.
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Introduction
Prostate cancer (Pca) is the second leading cause of can-
cer-related death in American men and is becoming a
common cancer increasing in China. Despite recently
great progress in the diagnosis and management of local-
ized disease, there continues to be a need for new diagnos-
tic markers that can accurately discriminate between
indolent and aggressive variants of Pca. There also contin-
ues to be a need for the identification and characterization
of potential new therapeutic targets on Pca cells. Current
diagnostic and therapeutic modalities for recurrent and
metastatic Pca have been limited by a lack of specific tar-
get antigens of Pca.
Although a number of prostate-specific genes have been
identified (i.e. prostate specific antigen, prostatic acid
phosphatase, glandular kallikrein 2), the majority of these
are secreted proteins not ideally suited for many immuno-
logical strategies. So, the identification of new cell surface
antigens is critical to the development of new diagnostic
and therapeutic approaches to the management of Pca.
Reiter RE et al [1] reported the identification of prostate
stem cell antigen (PSCA), a cell surface antigen that is pre-
dominantly prostate specific. The PSCA gene encodes a
123 amino acid glycoprotein, with 30% homology to
stem cell antigen 2 (Sca 2). Like Sca-2, PSCA also belongs
to a member of the Thy-1/Ly-6 family and is anchored by
a glycosylphosphatidylinositol (GPI) linkage. mRNA in
situ hybridization (ISH) localized PSCA expression in nor-
mal prostate to the basal cell epithelium, the putative
stem cell compartment of prostatic epithelium, suggesting
that PSCA may be a marker of prostate stem/progenitor
cells.
In order to examine the status of PSCA protein and mRNA
expression in human Pca and validate it as a potential
diagnostic and therapeutic target for Pca, we used immu-
nohistochemistry (IHC) and in situ hybridization (ISH)
simultaneously, and conducted PSCA protein and mRNA
expression analyses in paraffin-embedded tissue speci-
mens of benign prostatic hyperplasia (BPH, n = 20), pros-
tate intraepithelial neoplasm (PIN, n = 20) and prostate
cancer (Pca, n = 48). Furthermore, we evaluated the possi-
ble correlation of PSCA expression level with Pca tumori-
genesis, grade, stage and progression to androgen-
independence.
Materials and methods
Tissue samples
All of the clinical tissue specimens studied herein were
obtained from 80 patients of 57–84 years old by prostate-
ctomy, transurethral resection of prostate (TURP) or biop-
sies. The patients were classified as 20 cases of BPH, 20
cases of PIN, 40 cases of primary Pca, including 9 patients
with recurrent Pca and a history of androgen ablation
therapy (orchiectomy and/or hormonal therapy), who
were referred to as androgen-independent prostate can-
cers. Eight specimens were harvested from these andro-
gen-independent Pca patients prior to androgen ablation
treatment. Each tissue sample was cut into two parts, one
was fixed in 10% formalin for IHC and the other treated
with 4% paraformaldehyde/0.1 M PBS PH 7.4 in 0.1%
DEPC for 1 h for ISH analysis, and then embedded in par-
affin. All paraffin blocks examined were then cut into 5
µm sections and mounted on the glass slides specific for
IHC and ISH respectively in the usual fashion. H&E-
stained section of each Pca was evaluated and assigned a
Gleason score by the experienced urological pathologist at
our institution based on the criteria of Gleason score [2].
The Gleason sums are summarized in Table 1. Clinical
staging was performed according to Jewett-whitmore-
prout staging system, as shown in Table 2. In the category
of PIN, we graded the specimens into two groups, i.e. low
grade PIN (grade I – II) and high grade PIN (HGPIN,
grade III) on the basis of literatures [3,4].
Immunohistochemical (IHC) analysis
Briefly, tissue sections were deparaffinized, dehydrated,
and subjected to microwaving in 10 mmol/L citrate
buffer, PH 6.0 (Boshide, Wuhan, China) in a 900 W oven
for 5 min to induce epitope retrieval. Slides were allowed
to cool at room temperature for 30 min. A primary mouse
antibody specific to human PSCA (Boshide, Wuhan,
China) with a 1:100 dilution was applied to incubate with
the slides at room temperature for 2 h. Labeling was
detected by sequentially adding biotinylated secondary
antibodies and strepavidin-peroxidase, and localized
using 3,3'-diaminobenzidine reaction. Sections were then
counterstained with hematoxylin. Substitution of the pri-
mary antibody with phosphate-buffered-saline (PBS)
served as a negative-staining control.
mRNA in situ hybridization (ISH)
Five-µm-thick tissue sections were deparaffinized and
dehydrated, then digested in pepsin solution (4 mg/ml in
3% citric acid) for 20 min at 37.5°C, and further proc-
essed for ISH. Digoxigenin-labeled sense and antisense
human PSCA RNA probes (obtained from Boshide,
Wuhan, China) were hybridized to the sections at 48°C
overnight. The posthybridization wash with a high strin-
gency was performed sequentially at 37°C in 2 × standard
saline citrate (SSC) for 10 min, in 0.5 × SSC for 15 min
and in 0.2 × SSC for 30 min. The slides were then incu-
bated to biotinylated mouse anti-digoxigenin antibody at
37.5°C for 1 h followed by washing in 1 × PBS for 20 min
at room temperature, and then to strepavidin-peroxidase
at 37.5°C for 20 min followed by washing in 1 × PBS for
15 min at room temperature. Subsequently, the slides
were developed with diaminobenzidine and then coun-World Journal of Surgical Oncology 2004, 2 http://www.wjso.com/content/2/1/13
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terstained with hematoxylin to localize the hybridization
signals. Sections hybridized with the sense control probes
routinely did not show any specific hybridization signal
above background. All slides were hybridized with PBS to
substitute for the probes as a negative control.
Scoring methods
To determine the correlation between the results of PSCA
immunostaining and mRNA in situ hybridization, the
same scoring manners are taken in the present study for
PSCA protein staining by IHC and PSCA mRNA staining
by ISH. Each slide was read and scored by two independ-
ently experienced urological pathologists using Olympus
BX-41 light microscopes. The evaluation was done in a
blinded fashion. For each section, five areas of similar
grade were analyzed semiquantitatively for the fraction of
cells staining. Fifty percent of specimens were randomly
chosen and rescored to determine the degree of interob-
server and intraobserver concordance. There was greater
than 95% intra- and interobserver agreement.
The intensity of PSCA expression evaluated microscopi-
cally was graded on a scale of 0 to 3+ with 3 being the
highest expression observed (0, no staining; 1+, mildly
intense; 2+, moderately intense; 3+, severely intense). The
staining density was quantified as the percentage of cells
staining positive for PSCA with the primary antibody or
hybridization probe, as follows: 0 = no staining; 1 = posi-
tive staining in <25% of the sample; 2 = positive staining
in 25%–50% of the sample; 3 = positive staining in >50%
of the sample. Intensity score (0 to 3+) was multiplied by
the density score (0–3) to give an overall score of 0–9
[1,5]. In this way, we were able to differentiate specimens
that may have had focal areas of increased staining from
those that had diffuse areas of increased staining [6]. The
overall score for each specimen was then categorically
assigned to one of the following groups: 0 score, negative
expression; 1–2 scores, weak expression; 3–6 scores, mod-
erate expression; 9 score, strong expression.
Statistical analysis
Intensity and density of PSCA protein and mRNA expres-
sion in BPH, PIN and Pca tissues were compared using the
Chi-square and Student's t-test. Univariate associations
between PSCA expression and Gleason score, clinical
stage and progression to androgen-independence were
calculated using Fisher's Exact Test. For all analyses, p <
0.05 was considered statistically significant.
Results
PSCA expression in BPH
In general, PSCA protein and mRNA were expressed
weakly in individual samples of BPH. Some areas of
prostate expressed weak levels (composite score 1–2),
whereas other areas were completely negative (composite
score 0). Four cases (20%) of BPH had moderate expres-
sion of PSCA protein and mRNA (composite score 4–6)
by IHC and ISH. In 2/20 (10%) BPH specimens, PSCA
mRNA expression was moderate (composite score 3–6),
but PSCA protein expression was weak (composite score
Table 1: Correlation of PSCA expression with Gleason score
Intensity × frequency
Gleason score 0–6 (%) 9 (%)
2–4 5 (83) 1 (17)
5–7 19 (79) 5 (21)
8–10 5 (28) 13 (72)
Table 2: Correlation of PSCA expression with clinical stage
Intensity × frequency
Tumor stage 0–6 (%) 9 (%)
≤B 27 (67.5) 13 (32.5)
≥C 2 (25) 6 (75)World Journal of Surgical Oncology 2004, 2 http://www.wjso.com/content/2/1/13
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2) in one and negative (composite score 0) in the other.
PSCA expression was localized to the basal and secretory
epithelial cells, and prostatic stroma was almost negative
staining for PSCA protein and mRNA in all cases
examined.
PSCA expression in PIN
In this study, we detected weak or negative expression of
PSCA protein and mRNA (≤2 scores) in 7 of 9 (77.8%)
low grade PIN and in 2 of 11 (18.2%) HGPIN, and mod-
erate expression (3–6 scores) in the rest 2 low grade PIN
and 5 of 11 (45.5%) HGPIN. One HGPIN with moderate
PSCA mRNA expression (6 score) was found weak stain-
ing for PSCA protein (2 score) by IHC. Strong PSCA pro-
tein and mRNA expression (9 score) were detected in the
remaining 3 of 11 (27.3%) HGPIN. There was a statisti-
cally significant difference of PSCA protein and mRNA
expression levels observed between HGPIN and BPH (p <
0.05), but no statistical difference reached between low
grade PIN and BPH (p > 0.05).
PSCA expression in Pca
In order to determine if PSCA protein and mRNA can be
detected in prostate cancers and if PSCA expression levels
are increased in malignant compared with benign glands,
Forty-eight paraffin-embedded Pca specimens were ana-
lysed by IHC and ISH. It was shown that 19 of 48 (39.6%)
Pca samples stained very strongly for PSCA protein and
mRNA with a score of 9 and another 21 (43.8%) speci-
mens displayed moderate staining with scores of 4–6 (Fig-
ure 1). In addition, 4 specimens with moderate to strong
PSCA mRNA expression (scores of 4–9) had weak protein
staining (a score of 2) by IHC analyses. Overall, Pca
expressed a significantly higher level of PSCA protein and
mRNA than any other specimen category in this study (p
< 0.05, compared with BPH and PIN respectively). The
result demonstrates that PSCA protein and mRNA are
overexpressed by a majority of human Pca.
Correlation of PSCA expression with Gleason score in Pca
Using the semi-quantitative scoring method as described
in Materials and Methods, we compared the expression
level of PSCA protein and mRNA with Gleason grade of
Pca, as shown in Table 1. Prostate adenocarcinomas were
graded by Gleason score as 2–4 scores = well-differentia-
tion, 5–7 scores = moderate-differentiation and 8–10
scores = poor-differentiation [7]. Seventy-two percent of
Gleason scores 8–10 prostate cancers had very strong
staining of PSCA compared to 21% with Gleason scores
5–7 and 17% with 2–4 respectively, demonstrating that
poorly differentiated Pca had significantly stronger
expression of PSCA protein and mRNA than moderately
and well differentiated tumors (p < 0.05). As depicted in
Figure 1, IHC and ISH analyses showed that PSCA protein
and mRNA expression in several cases of poorly differen-
tiated Pca were particularly prominent, with more intense
and uniform staining. The results indicate that PSCA
expression increases significantly with higher tumor grade
in human Pca.
Correlation of PSCA expression with clinical stage in Pca
With regards to PSCA expression in every stage of Pca, we
showed the results in Table 2. Seventy-five percent of
locally advanced and node positive cancers (i.e. C-D
stages) expressed statistically high levels of PSCA versus
32.5% that were organ confined (i.e. A-B stages) (p <
0.05). The data demonstrate that PSCA expression
increases significantly with advanced tumor stage in
human Pca.
Correlation of PSCA expression with androgen-
independent progression of Pca
All 9 specimens of androgen-independent prostate can-
cers stained positive for PSCA protein and mRNA. Eight
specimens were obtained from patients managed prior to
androgen ablation therapy. Seven of eight (87.5%) of
these androgen-independent prostate cancers were in the
strongest staining category (score = 9), compared with
three out of eight (37.5%) of patients with androgen-
dependent cancers (p < 0.05). The results demonstrate
that PSCA expression increases significantly with progres-
sion to androgen-independence of human Pca.
It is evident from the results above that within a majority
of human prostate cancers the level of PSCA protein and
mRNA expression correlates significantly with increasing
grade, worsening stage and progression to androgen-inde-
pendence.
Correlation of PSCA immunostaining and mRNA in situ 
hybridization
In all 88 specimens surveyed herein, we compared the
results of PSCA IHC staining with mRNA ISH analysis.
Positive staining areas and its intensity and density scores
evaluated by IHC were identical to those seen by ISH in 79
of 88 (89.8%) specimens (18/20 BPH, 19/20 PIN and 42/
48 Pca respectively). Importantly, 27/27 samples with
PSCA mRNA composite scores of 0–2, 32/36 samples
with scores of 3–6 and 22/24 samples with a score of 9
also had PSCA protein expression scores of 0–2, 3–6 and
9 respectively. However, in 5 samples with PSCA mRNA
overall scores of 3–6 and in 2 with scores of 9 there were
less or negative PSCA protein expression (i.e. scores of 0–
4), suggesting that this may reflect posttranscriptional
modification of PSCA or that the epitopes recognized by
PSCA mAb may be obscured in some cancers. The data
demonstrate that the results of PSCA immunostaining
were consistent with those of mRNA ISH analysis, show-
ing a high degree of correlation between PSCA protein
and mRNA expression.World Journal of Surgical Oncology 2004, 2 http://www.wjso.com/content/2/1/13
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Representatives of PSCA IHC and ISH staining in Pca (A. IHC staining, B. ISH staining, ×200 magnification) Figure 1
Representatives of PSCA IHC and ISH staining in Pca (A. IHC staining, B. ISH staining, ×200 magnification). A1, B1: negative con-
trol of IHC and ISH. PBS replacing the primary antibody (A1) and hybridization with a sense PSCA probe (B1) showed no back-
ground staining. A2, B2: a moderately differentiated Pca (Gleason score = 3+3 = 6) with moderate staining (composite score = 
6) in all malignant cells; A2: IHC shows not only cell surface but also apparent cytoplasmic staining of PSCA protein. A3, B3: a 
poorly differentiated Pca (Gleason score = 4+4 = 8) with very strong staining (composite score = 9) in all malignant cells.World Journal of Surgical Oncology 2004, 2 http://www.wjso.com/content/2/1/13
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Discussion
PSCA is homologous to a group of cell surface proteins
that mark the earliest phase of hematopoietic develop-
ment. PSCA mRNA expression is prostate-specific in nor-
mal male tissues and is highly up-regulated in both
androgen-dependent and-independent Pca xenografts
(LAPC-4 tumors). We hypothesize that PSCA may play a
role in Pca tumorigenesis and progression, and may serve
as a target for Pca diagnosis and treatment. In this study,
IHC and ISH showed that in general there were weak or
absent PSCA protein and mRNA expression in BPH and
low grade PIN tissues. However, PSCA protein and mRNA
are widely expressed in HGPIN, the putative precursor of
invasive Pca, suggesting that up-regulation of PSCA is an
early event in prostate carcinogenesis. Recently, Reiter RE
et al [1], using ISH analysis, reported that 97 of 118 (82%)
HGPIN specimens stained strongly positive for PSCA
mRNA. A very similar finding was seen on mouse PSCA
(mPSCA) expression in mouse HGPIN tissues by Tran C.
P et al [8]. These data suggest that PSCA may be a new
marker associated with transformation of prostate cells
and tumorigenesis.
We observed that PSCA protein and mRNA are highly
expressed in a large percentage of human prostate cancers,
including advanced, poorly differentiated, androgen-
independent and metastatic cases. Fluorescence-activated
cell sorting and confocal/ immunofluorescent studies
demonstrated cell surface expression of PSCA protein in
Pca cells [9]. Our IHC expression analysis of PSCA shows
not only cell surface but also apparent cytoplasmic stain-
ing of PSCA protein in Pca specimens (Figure 1). One pos-
sible explanation for this is that anti-PSCA antibody can
recognize PSCA peptide precursors that reside in the cyto-
plasm. Also, it is possible that the positive staining that
appears in the cytoplasm is actually from the overlying
cell membrane [5]. These data seem to indicate that PSCA
is a novel cell surface marker for human Pca.
Our results show that elevated level of PSCA expression
correlates with high grade (i.e. poor differentiation),
increased tumor stage and progression to androgen-inde-
pendence of Pca. These findings support the original IHC
analyses by Gu Z et al [9], who reported that PSCA protein
expressed in 94% of primary Pca and the intensity of
PSCA protein expression increased with tumor grade,
stage and progression to androgen-independence. Our
results also collaborate the recent work of Han KR et al
[10], in which the significant association between high
PSCA expression and adverse prognostic features such as
high Gleason score, seminal vesicle invasion and capsular
involvement in Pca was found. It is suggested that PSCA
overexpression may be an adverse predictor for recur-
rence, clinical progression or survival of Pca. Hara H et al
[11] used RT-PCR detection of PSA, PSMA and PSCA in 1
ml of peripheral blood to evaluate Pca patients with poor
prognosis. The results showed that among 58 PCa
patients, each PCR indicated the prognostic value in the
hierarchy of PSCA>PSA>PSMA RT-PCR, and extraprostatic
cases with positive PSCA PCR indicated lower disease-pro-
gression-free survival than those with negative PSCA PCR,
demonstrating that PSCA can be used as a prognostic fac-
tor. Dubey P et al [12] reported that elevated numbers of
PSCA + cells correlate positively with the onset and devel-
opment of prostate carcinoma over a long time span in
the prostates of the TRAMP and PTEN +/- models com-
pared with its normal prostates. Taken together with our
present findings, in which PSCA is overexpressed from
HGPIN to almost frank carcinoma, it is reasonable and
possible to use increased PSCA expression level or
increased numbers of PSCA-positive cells in the prostate
samples as a prognostic marker to predict the potential
onset of this cancer. These data raise the possibility that
PSCA may have diagnostic utility or clinical prognostic
value in human Pca.
The cause of PSCA overexpression in Pca is not known.
One possible mechanism is that it may result from PSCA
gene amplification. In humans, PSCA is located on chro-
mosome 8q24.2 [1], which is often amplified in meta-
static and recurrent Pca and considered to indicate a poor
prognosis [13-15]. Interestingly, PSCA is in close proxim-
ity to the c-myc oncogene, which is amplified in >20% of
recurrent and metastatic prostate cancers [16,17]. Reiter
RE et al [18] reported that PSCA and MYC gene copy num-
bers were co-amplified in 25% of tumors (five out of
twenty), demonstrating that PSCA overexpression is asso-
ciated with PSCA and MYC coamplification in Pca. Gu Z
et al [9] recently reporteted that in 102 specimens availa-
ble to compare the results of PSCA immunostaining with
their previous mRNA ISH analysis, 92 (90.2%) had iden-
tically positive areas of PSCA protein and mRNA expres-
sion. Taken together with our findings, in which we
detected moderate to strong expression of PSCA protein
and mRNA in 34 of 40 (85%) Pca specimens examined
simultaneously by IHC and ISH analyses, it is demon-
strated that PSCA protein and mRNA overexpressed in
human Pca, and that the increased protein level of PSCA
was resulted from the upregulated transcription of its
mRNA.
At present, the regulation mechanisms of human PSCA
expression and its biological function are yet to be eluci-
dated. PSCA expression may be regulated by multiple fac-
tors [18]. Watabe T et al [19] reported that transcriptional
control is a major component regulating PSCA expression
levels. In addition, induction of PSCA expression may be
regulated or mediated through cell-cell contact and pro-
tein kinase C (PKC) [20]. Homologues of PSCA have
diverse activities, and have themselves been involved inWorld Journal of Surgical Oncology 2004, 2 http://www.wjso.com/content/2/1/13
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carcinogenesis. Signalling through SCA-2 has been dem-
onstrated to prevent apoptosis in immature thymocytes
[21]. Thy-1 is involved in T cell activation and transducts
signals through src-like tyrosine kinases [22]. Ly-6 genes
have been implicated both in tumorigenesis and in cell-
cell adhesion [23-25]. Cell-cell or cell-matrix interaction is
critical for local tumor growth and spread to distal sites.
From its restricted expression in basal cells of normal
prostate and its homology to SCA-2, PSCA may play a role
in stem/progenitor cell function, such as self-renewal (i.e.
anti-apoptosis) and/or proliferation [1]. Taken together
with the results in the present study, we speculate that
PSCA may play a role in tumorigenesis and clinical pro-
gression of Pca through affecting cell transformation and
proliferation. From our results, it is also suggested that
PSCA as a new cell surface antigen may have a number of
potential uses in the diagnosis, therapy and clinical prog-
nosis of human Pca. PSCA overexpression in prostate
biopsies could be used to identify patients at high risk to
develop recurrent or metastatic disease, and to discrimi-
nate cancers from normal glands in prostatectomy sam-
ples. Similarly, the detection of PSCA-overexpressing cells
in bone marrow or peripheral blood may identify and pre-
dict metastatic progression better than current assays,
which identify only PSA-positive or PSMA-positive pros-
tate cells.
In summary, we have shown in this study that PSCA pro-
tein and mRNA are maintained in expression from
HGPIN through all stages of Pca in a majority of cases,
which may be associated with prostate carcinogenesis and
correlate positively with high tumor grade (poor cell dif-
ferentiation), advanced stage and androgen-independent
progression. PSCA protein overexpression is due to the
upregulation of its mRNA transcription. The results sug-
gest that PSCA may be a promising molecular marker for
the clinical prognosis of human Pca and a valuable target
for diagnosis and therapy of this tumor.
Competing interests
None declared.
References
1. Reiter RE, Gu Z, Watabe T, Thomas G, Szigeti K, David E, Wahl M,
Nisitani S, Yamashiro J, Le Beau MM, Loda M, Witte ON: Prostate
stem cell antigen: a cell surface marker overexpressed in
prostate cancer. Proc Natl Acad Sci USA 1998, 95:1735-1740.
2. Gleason DF: Histologic grading and clinical staging of prostatic
carcinoma. In: Urologic Pathology: The Prostate Edited by: Tannebaum
M. Philadelphia, Lea & Febiger; 1977:171-197. 
3. Brawer MK: Prostatic intraepithelial neoplasia: a premalig-
nant lesion. Hum Pathol 1992, 23:242-248.
4. Amin MB, Ro JY, Ayala AC: Prostatic intraepithelial neoplasia:
relationship to adenocarcinoma of prostate. Pathol Annu 1994,
29:1-30.
5. Amara N, Palapattu GS, Schrage M, Gu Z, Thomas GV, Dorey F, Said
J, Reiter RE: Prostate stem cell antigen is overexpressed in
human transitional cell carcinoma.  Cancer Res 2001,
61:4660-4665.
6. Hanas JS, Lerner MR, Lightfoot SA, Raczkowski C, Kastens DJ, Brack-
ett DJ, Postier RG: Expression of the cyclin-dependent kinase
inhibitor p21 (WAF1/CIP1) and p53 tumor suppressor in
dysplastic progression and adenocarcinoma in Barrett
esophagus. Cancer (Phila) 1999, 86:756-763.
7. Egevad L, Gramfors T, Karlberg L: Prognostic value of the
Gleason score in prostate cancer. BJU Int 2002, 89:538-542.
8. Tran CP, Lin C, Yamashiro J, Reiter RE: Prostate stem cell antigen
is a marker of late intermediate prostate epithelial cells. Mol
Cancer Res 2002, 1:113-121.
9. Gu Z, Thomas G, Yamashiro J, Shintaku IP, Dorey F, Raitano A, Witte
ON, Said JW, Loda M, Reiter RE: Prostate stem cell antigen
(PSCA) expression increases with high Gleason score,
advanced stage and bone metastasis in prostate cancer. Onco-
gene 2000, 19:1288-1296.
10. Han KR, Seligson DB, Liu X, Horvath S, Shintaku PI, Thomas GV, Said
JW, Reiter RE: Prostate stem cell antigen expression is associ-
ated with gleason score, seminal vesicle invasion and capsu-
lar invasion in prostate cancer. J Urol 2004, 171:1117-1121.
11. Hara H, Kasahara T, Kawasaki T, Bilim V, Obara K, Takahashi K, Tom-
ita Y: Reverse Transcription-Polymerase Chain Reaction
Detection of Prostate-specific Antigen, Prostate-specific
Membrane Antigen, and Prostate Stem Cell Antigen in One
Milliliter of Peripheral Blood. Clin Cancer Res 2002, 8:1794-1799.
12. Dubey P, Wu H, Reiter RE, Witte ON: Alternative pathways to
prostate carcinoma activate prostate stem cell antigen
expression. Cancer Res 2001, 61:3256-3261.
13. Visa korpi T, Kallioniemi AH, Syvanen AC, Hyytinen ER, Karhu R,
Tammela T, Isola JJ, Kallioniemi OP: Genetic changes in primary
and recrrent prostate cancer by comparative genomic
hybridization. Cancer Res 1995, 55:342-347.
14. Sato K, Qian J, Slezak JM, Lieber MM, Bostwick DG, Bergstralh EJ,
Jenkins RB: Clinical significance of alterations of chromosome
8 in high-grade, advanced, nonmetastatic prostate
carcinoma. J Natl Cancer Inst 1999, 91:1574-1580.
15. Van Den Berg C, Guan XY, Von Hoff D, Jenkins R, Bittner , Griffin C,
Kallioniemi O, Visakorpi , McGill , Herath J, Epstein J, Sarosdy M, Melt-
zer P, Trent J: DNA sequence amplification in human prostate
cancer identified by chromosome microdissection: potential
prognostic implications. Clin Cancer Res 1995, 1:11-18.
16. Jenkins RB, Qian J, Lieber MM, Bostwick DG: Detection of c-myc
oncogene amplification and chromosomal anomalies in met-
astatic prostatic carcinoma by fluorescence in situ
hybridization. Cancer Res 1997, 57:524-531.
17. Nupponen NN, Kakkola L, Koivisto P, Visakorpi T: Genetic altera-
tions in hormone-refractory recurrent prostate carcinomas.
Am J Pathol 1998, 153:141-148.
18. Reiter RE, Sato I, Thomas G, Qian J, Gu Z, Watabe T, Loda M, Jenkins
RB: Coamplification of prostate stem cell antigen (PSCA)
and MYC in locally advanced prostate cancer. Genes Chromo-
somes Cancer 2000, 27:95-103.
19. Watabe T, Lin M, Donjacour AA, Cunha GR, Witte ON, Reiter RE:
Growth, regeneration, and tumorigenesis of the prostate
activates the PSCA promoter.  Proc Natl Acad Sci USA 2002,
99:401-406.
20. Bahrenberg G, Brauers A, Joost HG, Jakse G: PSCA expression is
regulated by phorbol ester and cell adhesion in the bladder
carcinoma cell line RT112. Cancer Lett 2001, 168:37-43.
21. Noda S, Kosugi A, Saitoh S, Narumiya S, Hamaoka T: Protection
from anti-TCR/CD3-induced apoptosis in immature thymo-
cytes by a signal through thymic shared antigen-1/stem cell
antigen-2. J Exp Med 1996, 183:2355-2360.
22. Thomas PM, Samelson LE: The glycophosphatidylinositol-
anchored Thy-1 molecule interacts with the p60fyn protein
tyrosine kinase in T cells. J Biol Chem 1992, 267:12317-12322.
23. Bamezai A, Rock KL: Overexpressed Ly-6A.2 mediated cell-cell
adhesion by binding a ligand expressed on lymphoid cells.
Proc Natl Acad Sci USA 1995, 92:4294-4298.
24. Katz BZ, Eshel R, Sagi-Assif O, Witz IP: An association between
high Ly-6A/E expression on tumor cells and a highly malig-
nant phenotype. Int J Cancer 1994, 59:684-691.
25. Brakenhoff RH, Gerretsen M, Knippels EM, van Dijk M, van Essen H,
Weghuis DO, Sinke RJ, Snow GB, van Dongen GA: The human E48
antigen, highly homologous to the murine Ly-6 antigen ThB,
is a GPI-anchored molecule apparently involved in keratino-
cyte cell-cell adhesion. J Cell Biol 1995, 129:1677-1689.